Addendum

Pembrolizumab (colorectal cancer) - Addendum to Commission A21-36

Report documents

Indication:

First-line treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer

Result of dossier assessment:

Unchanged after addendum:

Patients for whom intensive therapy is appropriate: hint of considerable added benefit.
Patients for whom intensive therapy is not appropriate: added benefit not proven.

Federal Joint Committee (G-BA)

2021-09-16 A G-BA decision was published.

Project no.: A21-105
Commission: Commission awarded on 10.08.2021 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.